Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study.
AUTHORS
Schuetz
P ,
Birkhahn
R ,
Sherwin
R ,
Jones
AE ,
Singer
A ,
Kline
JA ,
Runyon
MS ,
Self
WH ,
Courtney
DM ,
Nowak
RM ,
Gaieski
DF ,
Ebmeyer
S ,
Johannes
S ,
Wiemer
JC ,
Schwabe
A ,
Shapiro
NI ,
. Critical care medicine. 2017 3 2; ().
- PMID: 28257335 [PubMed].
ABSTRACT
To prospectively validate that the inability to decrease procalcitonin levels by more than 80% between baseline and day 4 is associated with increased 28-day all-cause mortality in a large sepsis patient population recruited across the United States.
To prospectively validate that the inability to decrease procalcitonin levels by more than 80% between baseline and day 4 is associated with increased 28-day all-cause mortality in a large sepsis patient population recruited across the United States.
Tags: Alumni Publications 2017